Recombinant Human RET Kinase Protein (aa 658-1114, His & GST Tag)

SKU: PKSH030342

Size: 50μg

Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.

Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at < - 20°C.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: CDHF12;CDHR16;HSCR1;MEN2A;MEN2B;MTC1;PTC;RET-ELE1;RET51

Research Areas: Signal Transduction,Cancer

Conjugation:

Target Species: Human

Expression Host: Baculovirus-Insect Cells

Application: Enzyme

Fusion tag: N-His-GST

UNIProt ID: P07949

Accession: P07949-1

Background: RET proto-oncogene, also known as RET, is a cell-surface molecule that transduce signals for cell growth and differentiation. It contains 1 cadherin domain and 1 protein kinase domain. RET proto-oncogene belongs to the protein kinase superfamily, tyr protein kinase family. RET proto-oncogene is involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. It phosphorylates PTK2/FAK1 and regulates both cell death/survival balance and positional information. RET is required for the molecular mechanisms orchestration during intestine organogenesis, involved in the development of enteric nervous system and renal organogenesis during embryonic life, promotes the formation of Peyer's patch-like structures, modulates cell adhesion via its cleavage, involved in the development of the neural crest. RET proto-oncogene is active in the absence of ligand, triggering apoptosis. RET acts as a dependence receptor, in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. It also regulates nociceptor survival and size, triggers the differentiation of rapidly adapting (RA) mechanoreceptors, mediated several diseases such as neuroendocrine cancers.

Concentration:

Activity: The specific activity was determined to be 17 nmol/min/mg using synthetic TRK-C-derived Peptide (R11-VYSTDYYRLFNPS) as substrate.

Sequence: His 658-Ser 1114

Purity: > 90 % as determined by reducing SDS-PAGE.

Formulation: Supplied as sterile solution of 20mM Tris, 500mM NaCl, 10% glycerol, pH 8.0

Reconstitution: Not Applicable

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 76.7 kDa

ObservedMW: 70 kDa